VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences

March, 04 2021

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference. Presentation details can be found below. Barclays Global Healthcare Conference Day: Tuesday, March 9, 2021 Time: 8:00am Eastern Time Format: Fireside chat Webcast Link: https://kvgo.com/2021-global-healthcare-conference/vyne-therapeutics-2021     H.C. Wainwright Global Life Sciences Conference Day & Time: On demand, beginning 7:00am Eastern Time, Tuesday, March 9, 2021 Format: Fireside chat Webcast Link: https://journey.ct.events/view/7534c623-91e5-4fa6-9d64-6dbed8781b9a About VYNE Therapeutics Inc.VYNE’s mission is…

Read More

VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences

March, 04 2021

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference. Presentation details can be found below. Barclays Global Healthcare Conference Day: Tuesday, March 9, 2021 Time: 8:00am Eastern Time Format: Fireside chat Webcast Link: https://kvgo.com/2021-global-healthcare-conference/vyne-therapeutics-2021     H.C. Wainwright Global Life Sciences Conference Day & Time: On demand, beginning 7:00am Eastern Time, Tuesday, March 9, 2021 Format: Fireside chat Webcast Link: https://journey.ct.events/view/7534c623-91e5-4fa6-9d64-6dbed8781b9a About VYNE Therapeutics Inc.VYNE’s mission is…

Read More

VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update

March, 04 2021

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. “We continue to make progress in the trial and utilization of our two commercially launched products, driving market share in the acne and rosacea categories,” said David Domzalski, Chief Executive Officer of VYNE. “Our R&D team has made significant strides in developing our investigational product pipeline, having successfully advanced FCD105, our minocycline-adapalene combination product candidate for moderate-to-severe acne, which we anticipate commencing a Phase…

Read More

VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update

March, 04 2021

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. “We continue to make progress in the trial and utilization of our two commercially launched products, driving market share in the acne and rosacea categories,” said David Domzalski, Chief Executive Officer of VYNE. “Our R&D team has made significant strides in developing our investigational product pipeline, having successfully advanced FCD105, our minocycline-adapalene combination product candidate for moderate-to-severe acne, which we anticipate commencing a Phase…

Read More